Skip to main content

Articles

Page 3 of 36

  1. Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome caused by pathogenic TP53 variants. The condition represents one of the most relevant genetic causes of cancer in children and adults due to its freq...

    Authors: Judith Penkert, Farina J. Strüwe, Christina M. Dutzmann, Beate B. Doergeloh, Emilie Montellier, Claire Freycon, Myriam Keymling, Heinz-Peter Schlemmer, Birte Sänger, Beatrice Hoffmann, Tanja Gerasimov, Claudia Blattmann, Sebastian Fetscher, Michael Frühwald, Simone Hettmer, Uwe Kordes…
    Citation: Journal of Hematology & Oncology 2022 15:107
    Content type: Correspondence Published on:

  2. This study prospectively compared the efficacy and safety between matched related donor-hematopoietic stem cell transplantation (MRD-HSCT) (n = 108) and immunosuppressive therapy (IST) plus eltrombopag (EPAG) (IS...

    Authors: Limin Liu, Meiqing Lei, Rong Fu, Bing Han, Xin Zhao, Rongrong Liu, Yanming Zhang, Wenjing Jiao, Miao Miao, Fengkui Zhang, Liansheng Zhang and Depei Wu
    Citation: Journal of Hematology & Oncology 2022 15:105
    Content type: Correspondence Published on:

  3. Characterized by the expression of the critical transcription factor forkhead box protein P3, regulatory T (Treg) cells are an essential part of the immune system, with a dual effect on the pathogenesis of aut...

    Authors: Yuheng Yan, Lan Huang, Yiming Liu, Ming Yi, Qian Chu, Dechao Jiao and Kongming Wu
    Citation: Journal of Hematology & Oncology 2022 15:104
    Content type: Review Published on:

  4. Patients with higher-risk myelodysplastic syndromes (MDS) refractory to hypomethylating agents (HMAs) have limited therapeutic options and an expected overall survival (OS) of 3–5 months. Eltanexor is an inves...

    Authors: Sangmin Lee, Sanjay Mohan, Jessica Knupp, Kamal Chamoun, Adrienne de Jonge, Fan Yang, Erkan Baloglu, Jatin Shah, Michael G. Kauffman, Sharon Shacham and Bhavana Bhatnagar
    Citation: Journal of Hematology & Oncology 2022 15:103
    Content type: Correspondence Published on:

  6. Hemophagocytic lymphohistiocytosis (HLH), particularly primary HLH (pHLH), is a rare, life-threatening disease. Germline genetic deficiency of 12 known HLH genes impairs cytotoxic degranulation in natural kill...

    Authors: Xiaoman Bi, Qing Zhang, Lei Chen, Dan Liu, Yueying Li, Xiaoxi Zhao, Ya Zhang, Liping Zhang, Jingkun Liu, Chaoyi Wu, Zhigang Li, Yunze Zhao, Honghao Ma, Gang Huang, Xin Liu, Qian-fei Wang…
    Citation: Journal of Hematology & Oncology 2022 15:101
    Content type: Correspondence Published on:

  7. Authors: Yang Zhang, Xiaoyi Chen, Huamin Wang, Shanisha Gordon-Mitchell, Srabani Sahu, Tushar D. Bhagat, Gaurav Choudhary, Srinivas Aluri, Kith Pradhan, Plabani Sahu, Milagros Carbajal, Hui Zhang, Beamon Agarwal, Aditi Shastri, Robert Martell, Daniel Starczynowski…
    Citation: Journal of Hematology & Oncology 2022 15:100
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2022 15:70

  8. Both extracellular vesicles from mesenchymal stromal cell-derived human umbilical cords (hUC-EVs) and arsenic trioxides (ATOs) have been demonstrated to treat acute graft-versus-host disease (aGVHD) via immuno...

    Authors: Yan Su, Xueyan Sun, Xiao Liu, Qingyuan Qu, Liping Yang, Qi Chen, Fengqi Liu, Yueying Li, Qianfei Wang, Bo Huang, Xiao-Jun Huang and Xiao-Hui Zhang
    Citation: Journal of Hematology & Oncology 2022 15:99
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2022 15:102

  10. Drug resistance represents a major obstacle in cancer management, and the mechanisms underlying stress adaptation of cancer cells in response to therapy-induced hostile environment are largely unknown. As the ...

    Authors: Ping Jin, Jingwen Jiang, Li Zhou, Zhao Huang, Edouard C. Nice, Canhua Huang and Li Fu
    Citation: Journal of Hematology & Oncology 2022 15:97
    Content type: Review Published on:

  11. Ibrutinib is effective in the treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL) with an overall response rate (ORR) of 48%. However, factors associated with response (or lack thereof) to ibru...

    Authors: Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara K. Moyo, Nishitha Reddy, Julia Sheets, David M. Weiner, Praveen Ramakrishnan Geethakumari, Malathi Kandarpa, Ximena Jordan Bruno, Colin Thomas, Michael C. Churnetski, Andrew Hsu, Luke Zurbriggen, Cherie Tan…
    Citation: Journal of Hematology & Oncology 2022 15:96
    Content type: Correspondence Published on:

  12. Chemotherapy combined with or without targeted therapy is the fundamental treatment for metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs and the biological characterist...

    Authors: Junyong Weng, Shanbao Li, Zhonglin Zhu, Qi Liu, Ruoxin Zhang, Yufei Yang and Xinxiang Li
    Citation: Journal of Hematology & Oncology 2022 15:95
    Content type: Review Published on:

  13. Epidermal growth factor receptor (EGFR), the receptor for members of the epidermal growth factor family, regulates cell proliferation and signal transduction; moreover, EGFR is related to the inhibition of tum...

    Authors: Kunyu Shi, Guan Wang, Junping Pei, Jifa Zhang, Jiaxing Wang, Liang Ouyang, Yuxi Wang and Weimin Li
    Citation: Journal of Hematology & Oncology 2022 15:94
    Content type: Review Published on:

  14. Bladder cancer is the most common malignant tumor of the urinary system. Surgical resection and chemotherapy are the two mainstream treatments for bladder cancer. However, the outcomes are not satisfactory for...

    Authors: Wenlong Zhang, Xin He, Haoli Yin, Wenmin Cao, Tingsheng Lin, Wei Chen, Wenli Diao, Meng Ding, Hao Hu, Wenjing Mo, Qing Zhang and Hongqian Guo
    Citation: Journal of Hematology & Oncology 2022 15:93
    Content type: Research Published on:

  15. Post-market analyses revealed unanticipated links between first-generation Bruton’s tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension. Yet, whether this is seen with novel se...

    Authors: Sunnia T. Chen, Leylah Azali, Lindsay Rosen, Qiuhong Zhao, Tracy Wiczer, Marilly Palettas, John Gambril, Onaopepo Kola-Kehinde, Patrick Ruz, Sujay Kalathoor, Kerry Rogers, Adam Kittai, Michael Grever, Farrukh Awan, John C. Byrd, Jennifer Woyach…
    Citation: Journal of Hematology & Oncology 2022 15:92
    Content type: Research Published on:

  16. p53, encoded by the tumor suppressor gene TP53, is one of the most important tumor suppressor factors in vivo and can be negatively regulated by MDM2 through p53–MDM2 negative feedback loop. Abnormal p53 can b...

    Authors: Haohao Zhu, Hui Gao, Yingying Ji, Qin Zhou, Zhiqiang Du, Lin Tian, Ying Jiang, Kun Yao and Zhenhe Zhou
    Citation: Journal of Hematology & Oncology 2022 15:91
    Content type: Review Published on:

  17. Tyrosine kinase inhibitors (TKIs) have vastly improved long-term outcomes for patients with chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second- and third-generation TKIs were devel...

    Authors: Valentin García-Gutiérrez, Massimo Breccia, Elias Jabbour, Michael Mauro and Jorge E. Cortes
    Citation: Journal of Hematology & Oncology 2022 15:90
    Content type: Review Published on:

  18. Vascular endothelial growth factor receptors (VEGFRs) are a family of receptor protein tyrosine kinases that play an important role in the regulation of tumor-induced angiogenesis. Currently, VEGFR inhibitors ...

    Authors: Yun Liu, Yang Li, Yuxi Wang, Congcong Lin, Dan Zhang, Juncheng Chen, Liang Ouyang, Fengbo Wu, Jifa Zhang and Lei Chen
    Citation: Journal of Hematology & Oncology 2022 15:89
    Content type: Review Published on:

  19. Relapsed or refractory (R/R) acute myeloid leukemia (AML) has a poor prognosis. In this study, we evaluated chimeric antigen receptor (CAR) T cell therapy targeting CLL-1 in adults with R/R AML patients. Patie...

    Authors: Xin Jin, Meng Zhang, Rui Sun, Hairong Lyu, Xia Xiao, Xiaomei Zhang, Fan Li, Danni Xie, Xia Xiong, Jiaxi Wang, Wenyi Lu, Hongkai Zhang and Mingfeng Zhao
    Citation: Journal of Hematology & Oncology 2022 15:88
    Content type: Correspondence Published on:

  20. The development of combination immunotherapy based on the mediation of regulatory mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep understanding of tumor immunology must inv...

    Authors: Liangliang Xu, Chang Zou, Shanshan Zhang, Timothy Shun Man Chu, Yan Zhang, Weiwei Chen, Caining Zhao, Li Yang, Zhiyuan Xu, Shaowei Dong, Hao Yu, Bo Li, Xinyuan Guan, Yuzhu Hou and Feng-Ming Kong
    Citation: Journal of Hematology & Oncology 2022 15:87
    Content type: Review Published on:

  21. LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports showed a remarkable efficacy of LCAR-B38M in patients with relapsed/re...

    Authors: Wan-Hong Zhao, Bai-Yan Wang, Li-Juan Chen, Wei-Jun Fu, Jie Xu, Jie Liu, Shi-Wei Jin, Yin-Xia Chen, Xing-Mei Cao, Yun Yang, Yi-Lin Zhang, Fang-Xia Wang, Peng-Yu Zhang, Bo Lei, Liu-Fang Gu, Jian-Li Wang…
    Citation: Journal of Hematology & Oncology 2022 15:86
    Content type: Research Published on:

  22. Metastasis and chemoresistance are major culprits of cancer mortality, but factors contributing to these processes are incompletely understood.

    Authors: Hsin-Yi Chen, Shu-Jou Chan, Xinxin Liu, An-Chi Wei, Ru-In Jian, Kuan-Wei Huang, Yaw-Dong Lang, Jou-Ho Shih, Chun-Chieh Liao, Chiu-Lin Luan, Yu-Tung Kao, Shang-Yin Chiang, Pei-Wen Hsiao, Yuh-Shan Jou, Yunching Chen and Ruey-Hwa Chen
    Citation: Journal of Hematology & Oncology 2022 15:85
    Content type: Research Published on:

  23. The tumor microenvironment (TME), which is regulated by intrinsic oncogenic mechanisms and epigenetic modifications, has become a research hotspot in recent years. Characteristic features of TME include hypoxi...

    Authors: Fusheng Zhang, Haiyang Liu, Meiqi Duan, Guang Wang, Zhenghou Zhang, Yutian Wang, Yiping Qian, Zhi Yang and Xiaofeng Jiang
    Citation: Journal of Hematology & Oncology 2022 15:84
    Content type: Review Published on:

  24. Cancer is one of the leading causes of death worldwide, and the factors responsible for its progression need to be elucidated. Exosomes are structures with an average size of 100 nm that can transport proteins...

    Authors: Mahshid Deldar Abad Paskeh, Maliheh Entezari, Sepideh Mirzaei, Amirhossein Zabolian, Hossein Saleki, Mohamad Javad Naghdi, Sina Sabet, Mohammad Amin Khoshbakht, Mehrdad Hashemi, Kiavash Hushmandi, Gautam Sethi, Ali Zarrabi, Alan Prem Kumar, Shing Cheng Tan, Marios Papadakis, Athanasios Alexiou…
    Citation: Journal of Hematology & Oncology 2022 15:83
    Content type: Review Published on:

  25. Much higher risk of cancer has been found in diabetes patients. Insulin receptor (IR) and insulin-like growth factor 1 receptor (IGF1R) have been extensively studied in both breast cancer and diabetes therapie...

    Authors: Thi Ngoc Quynh Nguyen, Samil Jung, Hai Anh Nguyen, BeomSuk Lee, Son Hai Vu, Davaajargal Myagmarjav, Hye Hyeon Eum, Hae-Ock Lee, Taeyeon Jo, Yeongseon Choi and Myeong-Sok Lee
    Citation: Journal of Hematology & Oncology 2022 15:82
    Content type: Correspondence Published on:

  26. Recipients after hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor T-cell (CAR-T) therapy are at increased risk for unfavorable outcomes after SARS-CoV-2 infection. The efficacy of CO...

    Authors: Xi Wu, Lu Wang, Lu Shen, Lin He and Kefu Tang
    Citation: Journal of Hematology & Oncology 2022 15:81
    Content type: Correspondence Published on:

  27. Despite recent advances in cancer therapeutics, glioblastoma (GBM) remains one of the most difficult cancers to treat in both the primary and recurrent settings. GBM presents a unique therapeutic challenge giv...

    Authors: Daniel Kreatsoulas, Chelsea Bolyard, Bill X. Wu, Hakan Cam, Pierre Giglio and Zihai Li
    Citation: Journal of Hematology & Oncology 2022 15:80
    Content type: Review Published on:

  28. Capmatinib and tepotinib are guideline-recommended front-line treatments for non-small-cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations (METex14). However, the emergence of acquired resistanc...

    Authors: Toshio Fujino, Kenichi Suda, Takamasa Koga, Akira Hamada, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh and Tetsuya Mitsudomi
    Citation: Journal of Hematology & Oncology 2022 15:79
    Content type: Research Published on:

  29. Multiple myeloma (MM) is a plasma cell malignancy that affects an increasing number of patients worldwide. Despite all the efforts to understand its pathogenesis and develop new treatment modalities, MM remain...

    Authors: David Kegyes, Catalin Constantinescu, Louise Vrancken, Leo Rasche, Celine Gregoire, Bogdan Tigu, Diana Gulei, Delia Dima, Alina Tanase, Hermann Einsele, Stefan Ciurea, Ciprian Tomuleasa and Jo Caers
    Citation: Journal of Hematology & Oncology 2022 15:78
    Content type: Review Published on:

  30. Hypoxia, a common feature of the tumor microenvironment in various types of cancers, weakens cytotoxic T cell function and causes recruitment of regulatory T cells, thereby reducing tumoral immunogenicity. Stu...

    Authors: Qinghua Wu, Li You, Eugenie Nepovimova, Zbynek Heger, Wenda Wu, Kamil Kuca and Vojtech Adam
    Citation: Journal of Hematology & Oncology 2022 15:77
    Content type: Review Published on:

  31. Urothelial carcinoma (UC) is the most common pathological type of bladder cancer, a malignant tumor. However, an integrated multi-omics analysis of the Chinese UC patient cohort is lacking.

    Authors: Ning Xu, Zhenmei Yao, Guoguo Shang, Dingwei Ye, Haixing Wang, Hailiang Zhang, Yuanyuan Qu, Fujiang Xu, Yunzhi Wang, Zhaoyu Qin, Jiajun Zhu, Fan Zhang, Jinwen Feng, Sha Tian, Yang Liu, Jianyuan Zhao…
    Citation: Journal of Hematology & Oncology 2022 15:76
    Content type: Research Published on:

  32. BH3-mimetics are a novel drug class of small molecule inhibitors of BCL2 family proteins which restore apoptosis in malignant cells. The only currently approved BH3-mimetic, the selective BCL2 inhibitor veneto...

    Authors: Thomas E. Lew and John F. Seymour
    Citation: Journal of Hematology & Oncology 2022 15:75
    Content type: Review Published on:

  33. Natural killer (NK)/T-cell lymphomas are aggressive malignancies with a predilection for Asian and South American populations. Epstein–Barr virus (EBV) infection in lymphoma cells is universal. Predominantly e...

    Authors: Eric Tse, Wei-Li Zhao, Jie Xiong and Yok-Lam Kwong
    Citation: Journal of Hematology & Oncology 2022 15:74
    Content type: Review Published on:

  34. Despite tremendous success of molecular targeted therapy together with immunotherapy, only a small subset of patients can benefit from them. Chemotherapy remains the mainstay treatment for most of tumors inclu...

    Authors: Yao Jiang, Wei Huang, Xiaojiao Sun, Xiaozhou Yang, Youming Wu, Jiaojiao Shi, Ji Zheng, Shujie Fan, Junya Liu, Jun Wang, Zhen Liang, Nan Yang, Zhenming Liu and Yanyong Liu
    Citation: Journal of Hematology & Oncology 2022 15:73
    Content type: Correspondence Published on:

  35. Ferroptosis, a novel non-apoptotic form of cell death, can induce tumor cell death and treatment resistance. Lipid metabolism is closely related to ferroptosis; however, the effect of mammary adipocytes on bre...

    Authors: Yizhao Xie, Biyun Wang, Yannan Zhao, Zhonghua Tao, Ye Wang, Guangliang Chen and Xichun Hu
    Citation: Journal of Hematology & Oncology 2022 15:72
    Content type: Correspondence Published on:

  36. Authors: Jadwiga Węcławek-Tompol, Zuzanna Zakrzewska, Olga Gryniewicz-Kwiatkowska, Filip Pierlejewski, Ewa Bień, Agnieszka Zaucha-Prażmo, Olga Zając-Spychała, Anna Szmydki-Baran, Agnieszka Mizia-Malarz, Wioletta Bal, Małgorzata Sawicka-Żukowska, Agnieszka Kruk, Tomasz Ociepa, Anna Raciborska, Agnieszka Książek, Tomasz Szczepański…
    Citation: Journal of Hematology & Oncology 2022 15:71
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2021 14:163

  37. Advanced pancreatic ductal adenocarcinoma (PDAC) is usually an incurable malignancy that needs newer therapeutic targets. Interleukin-1 receptor accessory protein (IL1RAP) is an innate immune mediator that reg...

    Authors: Yang Zhang, Xiaoyi Chen, Huamin Wang, Shanisha Gordon-Mitchell, Srabani Sahu, Tushar D. Bhagat, Gaurav Choudhary, Srinivas Aluri, Kith Pradhan, Plabani Sahu, Milagros Carbajal, Hui Zhang, Beamon Agarwal, Aditi Shastri, Robert Martell, Daniel Starczynowski…
    Citation: Journal of Hematology & Oncology 2022 15:70
    Content type: Letter to the Editor Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2022 15:100

  38. International clinical practice guidelines have progressively endorsed direct oral anticoagulants (DOACs) as an alternative to low-molecular-weight heparins (LMWHs) monotherapy for the initial and long-term tr...

    Authors: Corinne Frere, Dominique Farge, Deborah Schrag, Pedro H. Prata and Jean M. Connors
    Citation: Journal of Hematology & Oncology 2022 15:69
    Content type: Correspondence Published on:

  39. Although chimeric antigen receptor (CAR)-modified adoptive T cell therapy is a promising immunotherapy for hematological malignancies, the efficacy improvement in relapsed/refractory acute lymphoblastic leukem...

    Authors: Peilong Lai, Xiaomei Chen, Yulian Wang, Jinghua Wang, Yuchen Zhang, Suxia Geng, Peng Li, Xin Du, Jianyu Weng and Duanqing Pei
    Citation: Journal of Hematology & Oncology 2022 15:68
    Content type: Correspondence Published on:

  40. Although messenger RNA (mRNA) vaccines have established efficacy for prevention of severe SARS-CoV2 infection in the general population, their effectiveness in patients with malignancy, especially those on ant...

    Authors: Anthony Rooney, Cory Bivona, Ben Liu, David Streeter, Han Gong and Qamar Khan
    Citation: Journal of Hematology & Oncology 2022 15:67
    Content type: Letter to the Editor Published on:

  41. The World Health Organization has defined a list of adverse events of special interest (AESI) for safety surveillance of vaccines. AESI have not been adequately assessed following COVID-19 vaccination in patie...

    Authors: Wei Kang, Jessica J. P. Shami, Vincent K. C. Yan, Xuxiao Ye, Joseph E. Blais, Xue Li, Victor H. F. Lee, Celine S. L. Chui, Francisco T. T. Lai, Eric Y. F. Wan, Carlos K. H. Wong, Ian C. K. Wong and Esther W. Chan
    Citation: Journal of Hematology & Oncology 2022 15:66
    Content type: Brief Report Published on:

  42. Conditioning of the bone marrow prior to haematopoietic stem cell transplant is essential in eradicating the primary cause of disease, facilitating donor cell engraftment and avoiding transplant rejection via ...

    Authors: James M. Griffin, Fiona M. Healy, Lekh N. Dahal, Yngvar Floisand and John F. Woolley
    Citation: Journal of Hematology & Oncology 2022 15:65
    Content type: Review Published on:

  43. Despite the increased usage of post-transplant cyclophosphamide (PTCy) in allogeneic hematopoietic stem cell transplantation (allo-HSCT), our knowledge of immune reconstitution post-allo-HSCT in the setting of...

    Authors: Chenchen Zhao, Matthew Bartock, Bei Jia, Neal Shah, David F. Claxton, Baldeep Wirk, Kevin L. Rakszawski, Myles S. Nickolich, Seema G. Naik, Witold B. Rybka, W Christopher C. Ehmann, Raymond J. Hohl, Jessica Valentin, Michelle Bernas-Peterson, Emily M. Gerber, Michele Zimmerman…
    Citation: Journal of Hematology & Oncology 2022 15:64
    Content type: Correspondence Published on:

  44. N7-methylguanosine (m7G), one of the most prevalent RNA modifications, has recently attracted significant attention. The m7G modification actively participates in biological and pathological functions by affecti....

    Authors: Yuejun Luo, Yuxin Yao, Peng Wu, Xiaohui Zi, Nan Sun and Jie He
    Citation: Journal of Hematology & Oncology 2022 15:63
    Content type: Review Published on:

  45. Neoadjuvant immunotherapy is emerging as novel effective intervention in lung cancer, but study to unearth effective surrogates indicating its therapeutic outcomes is limited. We investigated the genetic chang...

    Authors: Zhen Zhou, Zhengping Ding, Jie Yuan, Shengping Shen, Hong Jian, Qiang Tan, Yunhai Yang, Zhiwei Chen, Qingquan Luo, Xinghua Cheng, Yongfeng Yu, Xiaomin Niu, Liqiang Qian, Xiaoke Chen, Linping Gu, Ruijun Liu…
    Citation: Journal of Hematology & Oncology 2022 15:62
    Content type: Correspondence Published on:

  47. Extramedullary manifestations (EM) are rare in acute myeloid leukemia (AML) and their impact on clinical outcomes is controversially discussed.

    Authors: Jan-Niklas Eckardt, Friedrich Stölzel, Desiree Kunadt, Christoph Röllig, Sebastian Stasik, Lisa Wagenführ, Korinna Jöhrens, Friederike Kuithan, Alwin Krämer, Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H. Brümmendorf, Ralph Naumann, Björn Steffen, Volker Kunzmann…
    Citation: Journal of Hematology & Oncology 2022 15:60
    Content type: Research Published on:

  48. Single-cell sequencing (SCS) is an emerging high-throughput technology that can be used to study the genomics, transcriptomics, and epigenetics at a single cell level. SCS is widely used in the diagnosis and t...

    Authors: Yingying Han, Dan Wang, Lushan Peng, Tao Huang, Xiaoyun He, Junpu Wang and Chunlin Ou
    Citation: Journal of Hematology & Oncology 2022 15:59
    Content type: Review Published on:

  50. Pevonedistat, the first small-molecule inhibitor of NEDD8-activating enzyme, has demonstrated clinical activity in Western patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). We rep...

    Authors: Hiroshi Handa, June-Won Cheong, Yasushi Onishi, Hiroatsu Iida, Yukio Kobayashi, Hyeoung-Joon Kim, Tzeon-Jye Chiou, Koji Izutsu, Olga Tsukurov, Xiaofei Zhou, Helene Faessel, Ying Yuan, Farhad Sedarati, Douglas V. Faller, Akiko Kimura and Shang-Ju Wu
    Citation: Journal of Hematology & Oncology 2022 15:56
    Content type: Letter to the Editor Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us